Lack of clinical efficacy of imatinib in metastatic melanoma

• Verfasst von: Ugurel, Selma [VerfasserIn]
• Verfasst von: Hildenbrand, Ralf [VerfasserIn]
• Verfasst von: Sucker, Antje [VerfasserIn]
• Verfasst von: Rittgen, Werner [VerfasserIn]
• Verfasst von: Schadendorf, Dirk [VerfasserIn]
• Titel: Lack of clinical efficacy of imatinib in metastatic melanoma
• Verf.angabe: S. Ugurel, R. Hildenbrand, A. Zimpfer, P. La Rosée, P. Paschka, A. Sucker, P. Keikavoussi, J.C. Becker, W. Rittgen, A. Hochhaus and D. Schadendorf
• E-Jahr: 2005
• Jahr: 20 April 2005
• Umfang: 8 S.
• Fussnoten: Gesehen am 05.02.2021
• Titel Quelle: Enthalten in: British journal of cancer
• Ort Quelle: Edinburgh : Nature Publ. Group, 1999
• Jahr Quelle: 2005
• Band/Heft Quelle: 92(2005), 8, Seite 1398-1405
• ISSN Quelle: 1532-1827
• DOI: doi:10.1038/sj.bjc.6602529
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1747459046

Abstract

This two-centre phase-II trial aimed at investigating the efficacy of imatinib in metastasised melanoma patients in correlation to the tumour expression profile of the imatinib targets c-kit and platelet-derived growth factor receptor (PDGF-R). The primary study end point was objective response according to RECIST, secondary end points were safety, overall and progression-free survival. In all, 18 patients with treatment-refractory advanced melanoma received imatinib 800 mg day−1. In 16 evaluable patients no objective responses could be observed. The median overall survival was 3.9 months, the median time to progression was 1.9 months. Tumour biopsy specimens were obtained from 12 patients prior to imatinib therapy and analysed for c-kit, PDGF-Rα and -Rβ expression by immunohistochemistry. In four cases, cell lines established from these tumour specimens were tested for the antiproliferative effects of imatinib and for functional mutations of genes encoding the imatinib target molecules. The tumour specimens stained positive for CD117/c-kit in nine out of 12 cases (75%), for PDGF-Rα in seven out of 12 cases (58%) and for PDGF-Rβ in eight out of 12 cases (67%). The melanoma cell lines showed a heterogenous expression of the imatinib target molecules without functional mutations in the corresponding amino-acid sequences. In vitro imatinib treatment of the cell lines showed no antiproliferative effect. In conclusion, this study did not reveal an efficacy of imatinib in advanced metastatic melanoma, regardless of the expression pattern of the imatinib target molecules c-kit and PDGF-R.